Validant — a prominent global consultancy specializing in quality, compliance, and regulatory services — has recently acquired Clinical Outcomes Solutions (COS), a distinguished leader in clinical outcomes assessment (COA) services.

This strategic move aligns with Validant’s commitment to offering comprehensive solutions to the life sciences industry.

Elevating COA Capabilities:

Founded in 2013, Clinical Outcomes Solutions has risen to a leadership position in the COA arena. The company's patient-centered approach and robust scientific and analytical capabilities have positioned it as a trailblazer in the fast-growing health economics and outcomes research (HEOR) market. COA plays a pivotal role by integrating the patient's perspective into drug development strategies.

Global Reach, Enhanced Services:

COS's headquarters in the UK and substantial presence in the US, with offices in Tucson (Arizona) and Chicago (Illinois), enable it to serve a diverse portfolio of biopharma clients worldwide. This acquisition aligns with Validant’s international growth strategy, marked by strategic partnerships with industry leaders in various regulatory and consultancy domains.

A Record of Strategic Collaborations:

The integration of Clinical Outcomes Solutions into the Validant group builds upon a series of impactful acquisitions. This includes Validant's acquisition of Greenleaf Health, a top-tier U.S. Food and Drug Administration (FDA) regulatory consulting firm, in April 2021. Previous acquisitions, such as Oriel STAT A MATRIX, IDEC, and DataRevive, further validate Validant's commitment to expanding its service offerings with trusted partners.

A Vision for Synergistic Growth:

Patrick Ronan, CEO of Validant, expressed enthusiasm for the integration:

“We are excited to welcome Clinical Outcomes Solutions into the Validant family. This collaboration empowers us to offer an even broader spectrum of services in the HEOR and COA realms. COS's expertise in clinical outcomes research perfectly aligns with our dedication to patient-centered solutions."

Patrick Ronan
CEO of Validant

Stacie Hudgens, CEO of COS, echoed this sentiment:

“Our journey of the past eight years has been dedicated to refining innovative scientific methodologies that give voice to patients. In Validant, we have found a shared commitment to patient-centric principles, and we are eager to combine our efforts to extend our reach and contribute positively to clients and patients globally."

Stacie Hudgens
CEO of COS

The acquisition was supported by Achelous Partners, providing investment banking and advisory services, and Taylor Wessing, offering legal counsel to COS shareholders. For Validant, OMM provided legal guidance, RSM Global provided financial and accounting counsel, Deloitte offered tax advisory, and Howden provided insurance expertise.

As Validant's journey of strategic collaborations continues, it remains committed to fostering excellence across various facets of the life sciences landscape. This acquisition marks another milestone in the pursuit of elevating patient care through innovative solutions and industry partnerships.